STEEPLE bleeding criteria: Difference between revisions
Jump to navigation
Jump to search
Line 15: | Line 15: | ||
* Clinically overt bleeding, causing a decrease in hemoglobin of ≥3 g/dL (or, if hemoglobin level is not available, a decrease in hematocrit of ≥10%) | * Clinically overt bleeding, causing a decrease in hemoglobin of ≥3 g/dL (or, if hemoglobin level is not available, a decrease in hematocrit of ≥10%) | ||
'''Minor''' | '''Minor''' | ||
Gross [[hematuria]] not associated with [[trauma]] (eg, from instrumentation) | *Gross [[hematuria]] not associated with [[trauma]] (eg, from instrumentation) | ||
[[Epistaxis]] that is prolonged, is repeated, or requires plugging or intervention | [[Epistaxis]] that is prolonged, is repeated, or requires plugging or intervention | ||
Gastrointestinal hemorrhage | Gastrointestinal hemorrhage |
Revision as of 17:32, 27 March 2013
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
STEEPLE bleeding criteria On the Web |
American Roentgen Ray Society Images of STEEPLE bleeding criteria |
Risk calculators and risk factors for STEEPLE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Steeple Bleeding Criteria
“ |
Safety and Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation [1] Major Bleeding
Minor Epistaxis that is prolonged, is repeated, or requires plugging or intervention Gastrointestinal hemorrhage
Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL Uncontrolled bleeding requiring protamine sulfate administration |
” |
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial". Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.